Cyclacel Pharmaceuticals (CYCC) Insider Trading & Ownership $0.37 -0.02 (-4.91%) (As of 11/15/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Cyclacel Pharmaceuticals (NASDAQ:CYCC) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage8.00%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$26,334.36Number OfInsiders Selling(Last 12 Months)0 Get CYCC Insider Trade Alerts Want to know when executives and insiders are buying or selling Cyclacel Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CYCC Insider Buying and Selling by Quarter Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Cyclacel Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/21/2023Paul McbarronInsiderBuy1,886$3.31$6,242.66 12/21/2023Spiro George RombotisCEOBuy6,070$3.31$20,091.70 (Data available from 1/1/2013 forward) CYCC Insider Trading Activity - Frequently Asked Questions Who is on Cyclacel Pharmaceuticals's Insider Roster? The list of insiders at Cyclacel Pharmaceuticals includes Paul Mcbarron, Sam L Barker, and Spiro George Rombotis. Learn more on insiders at CYCC. What percentage of Cyclacel Pharmaceuticals stock is owned by insiders? 8.00% of Cyclacel Pharmaceuticals stock is owned by insiders. Learn more on CYCC's insider holdings. Which Cyclacel Pharmaceuticals insiders have been buying company stock? The following insiders have purchased CYCC shares in the last 24 months: Paul Mcbarron ($6,242.66), and Spiro George Rombotis ($20,091.70). How much insider buying is happening at Cyclacel Pharmaceuticals? Insiders have purchased a total of 7,956 CYCC shares in the last 24 months for a total of $26,334.36 bought. Cyclacel Pharmaceuticals Key ExecutivesMr. Spiro George Rombotis (Age 65)President, CEO & Executive Director Compensation: $612.47kMr. Paul McBarron (Age 63)Executive VP of Finance, CFO, COO, Secretary & Executive Director Compensation: $321.61kDr. Brian Schwartz M.D. (Age 62)Interim Chief Medical Officer & Director Compensation: $53kMs. Gill Christie (Age 67)Director of Human Resources Grace KimInvestor Relations Executive More Insider Trading Tools from MarketBeat Related Companies Pasithea Therapeutics Insider Trading Processa Pharmaceuticals Insider Trading Gritstone bio Insider Trading Shuttle Pharmaceuticals Insider Trading InMed Pharmaceuticals Insider Trading Sunshine Biopharma Insider Trading Palisade Bio Insider Trading 180 Life Sciences Insider Trading MyMD Pharmaceuticals Insider Trading Virpax Pharmaceuticals Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics Partners This page (NASDAQ:CYCC) was last updated on 11/18/2024 by MarketBeat.com Staff From Our Partners5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | Sponsored🗓️ My First LIVE Event in 5 Years!Give us 60 minutes and we’ll show you how we’ve compressed 15 years of stock market gains into one day.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
